Analysis

  • 7 February 2020

    January’s top news stories

    A Phase I clinical trial of monoclonal antibody (mAb) CIS43LS against malaria started the enrolment of healthy adults at the NIH Clinical Center in Bethesda, Maryland, US, and Acceleron Pharma...

  • 3 January 2020

    2019 top news stories

    Athersys reports positive data from MultiStem cell therapy trial and CRISPR and Vertex treat first patient in gene-editing therapy trial. Clinicaltrialsarena.com wraps up the key headlines from 2019.

  • 6 December 2019

    November’s top news stories

    Eli Lilly and Boehringer Ingelheim started a Phase III clinical trial, EMPULSE, to evaluate whether Jardiance (empagliflozin) improves acute heart failure, and The Janssen Pharmaceutical Companies of Johnson & Johnson...

  • 25 November 2019

    Exploring efficiencies from eTMF with Cancer Research UK

    Creating electronic versions of documents and processes underlying clinical trials is becoming the norm. Cancer Research UK’s Stephen Nabarro walk us through its implementation of Veeva Vault eTMF two years...

  • 8 November 2019

    October’s top news stories

    GSK has initiated the Phase III EAGLE programme of gepotidacin for the treatment of uncomplicated urinary tract infection and urogenital gonorrhoea, and AstraZeneca has reported that a combination of Imfinzi...

  • 5 October 2019

    September’s top news stories

    NIH kick starts hunt for neuroprotective stroke treatments and Denali begins dosing Parkinson’s patients in Phase Ib trial. Clinicaltrialsarena.com wraps up the key headlines from September 2019.

  • 5 September 2019

    August’s top news stories

    Biopharmaceutical firm Retrophin reported that the Phase III clinical trial of fosmetpantotenate failed to meet endpoints in pantothenate kinase-associated neurodegeneration (PKAN) patients; and MyoKardia has commenced dosing of patients in...

  • 8 July 2019

    June’s top news stories

    AstraZeneca’s human monoclonal antibody Imfinzi (durvalumab) improved overall survival in the Phase III CASPIAN trial in first-line extensive-stage small cell lung cancer (SCLC).

Close
Close
Close

Go Top